Man, 43, is UK’s ‘first to die’ after taking sedative dubbed ‘zombie drug’
Xylazine lowers breathing and the heart rate – and causes large skin ulcers if injected.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A 43-year-old man has become the first person in the UK known to have died after taking a powerful sedative dubbed a “zombie drug”.
His death marks Britain’s first from xylazine, experts say.
The “dangerous” substance, used by vets as a tranquilliser for large animals, gets its nickname from its effects – it lowers breathing and the heart rate while, if injected, causing large skin ulcers.
It has contributed to an epidemic of drug deaths in the US, with research by the Food and Drug Administration showing it is prevalent in 7% of overdoses across the states.
The unnamed Briton, whose death is detailed in the Journal of Forensic and Legal Medicine from King’s College London (KCL), overdosed on a mix of xylazine, heroin, fentanyl and cocaine in May 2022.
A coroner determined the cause of death as acute aspiration pneumonitis, a condition often caused by inhaling toxins, and listed xylazine as a contributing factor.
Dr Caroline Copeland, senior author from KCL and director of the National Programme on Substance Abuse Deaths, said authorities do not know how widespread xylazine is in the UK as it is not included in standard drug screenings.
“This is a really concerning drug that hasn’t been detected in the UK before,” she said.
“This person was likely to have bought heroin and not known it was laced with xylazine and fentanyl.”